La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !

Amedisys Performance dei guadagni passati

Il passato criteri di controllo 3/6

Gli utili di Amedisys sono diminuiti a un tasso medio annuo di -22%, mentre il settore Healthcare ha visto gli utili crescere a un tasso medio annuo di 14.6%. I ricavi sono cresciuti crescere a un tasso medio annuo di 3.8%. Il ritorno sul capitale proprio di Amedisys è 7.8% e ha margini netti di 4%.

Informazioni chiave

-22.0%

Tasso di crescita degli utili

-22.2%

Tasso di crescita dell'EPS

Healthcare Crescita del settore	13.4%
Tasso di crescita dei ricavi	3.8%
Rendimento del capitale proprio	7.8%
Margine netto	4.0%
Ultimo aggiornamento sui guadagni	30 Jun 2024

Aggiornamenti sulle prestazioni recenti

Recent updates

Ripartizione dei ricavi e delle spese

Come Amedisys guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.

Storia dei guadagni e delle entrate

BMV:AMED * Ricavi, spese e utili (USD Millions )
Data	Ricavi	Guadagni	Spese G+A
30 Jun 24	2,290	92	782
31 Mar 24	2,251	-21	780
31 Dec 23	2,236	-10	780
30 Sep 23	2,228	3	774
30 Jun 23	2,229	2	769
31 Mar 23	2,234	112	763
31 Dec 22	2,223	119	754
30 Sep 22	2,220	121	745
30 Jun 22	2,216	140	736
31 Mar 22	2,222	191	723
31 Dec 21	2,214	209	711
30 Sep 21	2,206	220	1,033
30 Jun 21	2,196	247	911
31 Mar 21	2,117	202	785
31 Dec 20	2,072	184	668
30 Sep 20	2,021	166	216
30 Jun 20	1,972	128	214
31 Mar 20	1,980	127	219
31 Dec 19	1,956	127	608
30 Sep 19	1,889	127	207
30 Jun 19	1,812	124	197
31 Mar 19	1,731	123	189
31 Dec 18	1,663	119	185
30 Sep 18	1,626	88	181
30 Jun 18	1,583	71	178
31 Mar 18	1,546	42	178
31 Dec 17	1,511	30	177
30 Sep 17	1,474	43	181
30 Jun 17	1,456	40	187
31 Mar 17	1,438	46	190
31 Dec 16	1,419	37	196
30 Sep 16	1,391	41	198
30 Jun 16	1,358	38	193
31 Mar 16	1,313	38	188
31 Dec 15	1,266	-3	173
30 Sep 15	1,230	-7	158
30 Jun 15	1,204	-7	149
31 Mar 15	1,193	-10	142
31 Dec 14	1,188	13	147
30 Sep 14	1,191	-4	153
30 Jun 14	1,192	-103	161
31 Mar 14	1,203	-109	167
31 Dec 13	1,233	-93	170
30 Sep 13	1,278	-191	176

Guadagni di qualità: AMED * ha un grande una tantum perdita di $49.1M che ha avuto un impatto sui suoi ultimi 12 mesi di risultati finanziari pari a 30th June, 2024.

Margine di profitto in crescita: Gli attuali margini di profitto netti di AMED * (4%) AMED * sono più alti rispetto allo scorso anno (0.1%).

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Andamento degli utili: Gli utili di AMED * sono diminuiti del 22% all'anno negli ultimi 5 anni.

Accelerare la crescita: La crescita degli utili di AMED * nell'ultimo anno ( 3847.8% ) supera la media quinquennale ( -22% all'anno).

Guadagni vs Settore: La crescita degli utili AMED * nell'ultimo anno ( 3847.8% ) ha superato la percentuale del settore Healthcare 28.6%.

Amedisys Performance dei guadagni passati

Il passato criteri di controllo 3/6

Informazioni chiave

Aggiornamenti sulle prestazioni recenti

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

Recent updates

Michael P. North Leaves Amedisys, Inc. as Chief Information Officer and Compensation Committee of the Board of Directors, Effective August 31, 2024

Insufficient new directors

Option Care Health, Inc. (NasdaqGS:OPCH) cancelled the acquisition of Amedisys, Inc. (NasdaqGS:AMED).

Option Care Health, Inc. (NasdaqGS:OPCH) entered into an agreement and plan of merger to acquire Amedisys, Inc. (NasdaqGS:AMED) for $3.2 billion.

Insufficient new directors

Amedisys, Inc. (NasdaqGS:AMED) announces an Equity Buyback for $100 million worth of its shares.

Amedisys, Inc. to Report Q4, 2022 Results on Feb 15, 2023

Insufficient new directors

Insufficient new directors

Amedisys, Inc. Names Scott Ginn as Acting Chief Operating Officer

Amedisys, Inc. Announces CEO Changes

Amedisys, Inc. Provides Earnings Guidance for the Year 2022

Amedisys, Inc. to Report Q3, 2022 Results on Oct 26, 2022

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Resignation of David L. Kemmerly as Chief Legal and Government Affairs Officer

Second quarter 2022 earnings released: EPS: US$0.91 (vs US$2.46 in 2Q 2021)

High number of new directors

Amedisys, Inc. to Report Q2, 2022 Results on Jul 27, 2022

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 1000 Growth-Defensive Index

High number of new directors

Investor sentiment deteriorated over the past week

High number of new directors

Amedisys, Inc. Announces Promotion of Nick Muscato as Chief Strategy Officer

Amedisys, Inc. to Report Q1, 2022 Results on Apr 27, 2022

Amedisys, Inc. (NasdaqGS:AMED) completed the acquisition of Assets of AssistedCare Home Health, Inc. and RH Homecare Services, LLC.

High number of new directors

Amedisys, Inc. Announces Resignation of Richard A. Lechleiter from the Board of Directors

Investor sentiment improved over the past week

High number of new directors

Amedisys, Inc. (NasdaqGS:AMED) signed a definitive agreement to acquire Assets of AssistedCare Home Health, Inc.

Amedisys, Inc. (NasdaqGS : AMED) agreed to acquire Evolution Health, LLC from Emergency Medical Services LP Corporation.

Amedisys, Inc. to Report Q4, 2021 Results on Feb 23, 2022

High number of new directors

Investor sentiment deteriorated over the past week

Lead Independent Director recently bought Mex$3.0m worth of stock

Third quarter 2021 earnings released: EPS US$1.38 (vs US$2.20 in 3Q 2020)

Investor sentiment improved over the past week

High number of new directors

High number of new directors

Independent Director recently sold Mex$42m worth of stock

Second quarter 2021 earnings released: EPS US$2.46 (vs US$1.07 in 2Q 2020)

Investor sentiment deteriorated over the past week

High number of new directors

President & COO recently sold Mex$1.5m worth of stock

Amedisys, Inc. (NasdaqGS:AMED) entered into an Agreement to acquire Contessa Health, Inc. for $250 million.

Amedisys, Inc. (NasdaqGS:AMED) entered into a definitive agreement to acquire Home Health and Hospice Operations of Visiting Nurse Association.

Insider recently sold Mex$10m worth of stock

Amedisys, Inc. Provides Revenue Guidance for the Full Year 2021

First quarter 2021 earnings released: EPS US$1.52 (vs US$0.98 in 1Q 2020)

Amedisys, Inc. and Sound Physicians to Launch Home Health Advanced Pilot Program

Independent Director recently bought Mex$5.3m worth of stock

Revenue misses expectations

Full year 2020 earnings released: EPS US$5.64 (vs US$3.95 in FY 2019)

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. Announces Executive Changes

Amedisys, Inc. to Report Q4, 2020 Results on Feb 24, 2021

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Dynamic Index

Amedisys, Inc. and Option Care Health Inc. Collaborate to Provide Innovative COVID Therapy Access Model

Ivanetta Davis Samuels Joins Amedisys, Inc.'s Board of Director

Amedisys, Inc. to Report Q3, 2020 Results on Oct 28, 2020

Amedisys, Inc. to Report Q2, 2020 Results on Jul 28, 2020

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Growth-Defensive Index

Amedisys, Inc.(NasdaqGS:AMED) dropped from Russell 2000 Defensive Index

Ripartizione dei ricavi e delle spese

Storia dei guadagni e delle entrate

Flusso di cassa libero e analisi degli utili

Analisi della crescita degli utili nel passato

Rendimento del capitale proprio